Hormonal contraception and physiology: A research-based theory of discontinuation due to side effects

Studies in Family Planning

Volumn 36, Issue 1, 2005, Pages 13-32

  Vitzthum, Virginia J ^a   Ringheim, Karin ^b  

^a INDIANA UNIVERSITY   (United States)

^b Global Health Council   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE; ORAL CONTRACEPTIVE AGENT;

HORMONE; PHYSIOLOGY;

DEVELOPING COUNTRY; ETHNIC GROUP; FEMALE; HUMAN; PATIENT SATISFACTION; PHYSIOLOGY; REVIEW; SEXUAL BEHAVIOR; TREATMENT REFUSAL;

CONTRACEPTION BEHAVIOR; CONTRACEPTIVES, ORAL, HORMONAL; DEVELOPING COUNTRIES; ETHNIC GROUPS; FEMALE; HORMONES; HUMANS; PATIENT SATISFACTION; TREATMENT REFUSAL;

EID: 17544366733     PISSN: 00393665     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1728-4465.2005.00038.x     Document Type: Review

References (165)

1. Akerlund, M. 1997. "Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol." Acta Obstetrica et Gynecologica Scandinavica (Supplement) 164: 63-65.
2. Akhter, H.H., M.E. Chowdhury, M.H. Rahman, and M.A. Hussaid. 1996. "Report on a study to compare compliance, continuation and failure rates and reported side effects of the low dose and standard dose oral pill in rural Bangladesh." Dhaka: Bangladesh Institute of Research for Promotion of Essential and Reproductive Health Technologies. 110(43): xxiii.
3. Ali, Mohamed and John Cleland. 1995. "Contraceptive discontinuation in six developing countries: A cause-specific analysis." International Family Planning Perspectives 21(3): 92-97.
4. Archer, David F., Rodolphe Maheux, Anthony DelConte, Francis B. O'Brien, and the North American Levonorgestrel Study Group. 1997. "A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 mcg and ethinyl estrdiol 20 mcg." Contraception 55(3): 139-144.
5. Archer, David F., Rodolphe Maheux, Anthony DelConte, Francis B. O'Brien. 1999. "Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 mcg levonorgestrel and 20 mcg ethinyl estrdiol (Alesse)." American Journal of Obstetrics and Gynecology 181(5, part 2): S39-S44.
6. Bassol, Susana, Josue Garza-Flores, Maria C. Cravioto, Vicente Diaz-Sanchez, Kenneth Fotherby, Roberto Lichtenberg, and Gregorio Perez-Palacios. 1984. "Ovarian function following a single administration of DMPA at different doses." Fertility and Sterility 42(2): 216-222.
7. Bassol, Susana. et al. 2000. "Latin American experience with two low-dose oral contraceptives containing 30 mcg ethinylestradiol/75 mcg gestodene and 20 mcg ethinylestradiol/150 mcg desogestrel." Contraception 62(2): 131-135.
8. Bassol, Susana. et al. 2003. "A 13-month multicenter clinical experience of a low-dose monophasic oral contraceptive containing 20 mcg ethinylestradiol and 75 mcg gestodene in Latin American women." Contraception 67(5): 367-372.
9. Bentley, Gillian R. 1996. "Evidence for interpopulational variation in normal ovarian function and consequences for hormonal contraception." In Variability in Human Fertility. Eds. L. Rosetta and C.G.N. Mascie-Taylor. Cambridge: Cambridge University Press. Pp. 46-65.
10. Bergink, Willem, Roel Assendorp, Lenus Kloosterboer, Wim van Lier, Gerrit Voortman, and Ingelise Qvist. 1990. "Serum pharmacokinetics of orally administered desogestrel and binding of contraceptive progestogens to sex hormone-binding globulin." American Journal of Obstetrics and Gynecology 163(6, part 2): 2,132-2,137.
11. Blanc, Ann K., Siân Curtis, and Trevor N. Croft. 1999. "Does Contraceptive Discontinuation Matter? Quality of Care and Fertility Consequences." MEASURE Evaluation Technical Report No. 3. Calverton, MD: Macro International.
12. Blanc, Ann K., Siân Curtis, and Trevor N. Croft. 2002. "Monitoring contraceptive continuation: Links to fertility outcomes and quality of care." Studies in Family Planning 33(2): 127-140.
13. Bolivia Demographic and Health Survey (BDHS). 1998. . Accessed 12 February 2004.
14. Bolivia Demographic and Health Survey (BDHS). 2004. . Accessed 12 February 2004.
15. Briggs, M.H. and M. Briggs. 1972. "Steroid hormone concentrations in blood plasma from residents of Zambia, belonging to different ethnical groups." Acta Endocrinologica 70(3): 619-624.
16. Brill, K., T. Norpoth, J. Schnitker, and M. Albring. 1991. "Clinical experience with a modern low-dose oral contraceptive in almost 100,000 users." Contraception 43(2): 101-110.
17. Brincat, M., Y.M. Baron, and R. Galea. 2003. "How low can you get?" Annals of the New York Academy of Science 997: 158-162.
18. Brody, Steven A., A. Turkes, and Joseph W. Goldzieher. 1989. "Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethynyl estradiol-35 micrograms OC formulations: Are low-dose pills really lower?" Contraception 40(3): 269-284.
19. Bruce, Judith. 1990. "Fundamental elements of the quality of care: A simple framework." Studies in Family Planning 21(2): 61-91.
20. Burkman, R.T. 1997. "Oral contraceptive practice guidelines." In Benefits and Risks of OCs: A Current Perspective. Symposium monograph. Little Falls, NJ: Health Learning Systems. Pp. 37-42.
21. Canto de Cetina, Thelma E., Patricia Canto, and Manuel Ordonez Luna. 2001. "Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate." Contraception 63(3): 143-146.
22. Carr, B.R. and A. DelConte. 2002. "Using a low-dose contraceptive in women 35 years of age and over: 20 mcg estradiol/100 mcg levonorgestrel." Contraception 65(6): 397-402.
23. Contraception. 1992. "Letter to the editor." 45(5): 519-520.
24. The Contraception Report. 1997. "Trends in oral contraceptive development and utilization." The Contraception Report 7(5): 4-14.
25. The Contraception Report. 1999a. "Understanding oral contraceptive progestins: Classification of estranes and gonanes." The Contraception Report 9(6):9-10.
26. The Contraception Report. 1999b. "Understanding oral contraceptive progestins: Pharmacokinetics." The Contraception Report 10(1): 12-14.
27. The Contreception Report. 1999c. "Trends in oral contraceptive prescribing: An update." The Contraception Report 10(2): 12-14.
28. The Contraception Report. 2004. "Approach to oral contraceptive nuisance side effects." The Contraception Report 14(4): 13-15.
29. Cotton, N., J. Stanback, H. Maidouka, J.T. Taylor-Thomas, and T. Turk. 1992. "Early discontinuation of contraceptive use in Niger and the Gambia." International Family Planning Perspectives 18(4): 145-149.
30. Davis, A.R., S. Nowygrod, R. Shabsigh, and C. Westhoff. 2002. "The influence of vaginal bleeding on the sexual behavior of urban Hispanic women and men." Contraception 65(5): 351-355.
31. Deijen, J.B., K.J. Duyn, W.A. Jansen, and J.W. Klitsie. 1992. "Use of a monophasic, low dose oral contraceptive in relation to mental functioning." Contraception 46(4): 359-367.
32. Dickey, Richard P. 2002. "Letter to the editor." Contraception 65(6): 447.
33. Dickey, Richard P., C.W. Porter, and J.P. Wells. 1973. "Report of the survey team concerning the decrease in pill acceptors in the Philippines family planning program covering the period March 11-March 22,1973, prepared under the auspices of the American Public Health Association in agreement with the USAID." Unpublished.
34. Djerassi, Carl. 1992. The Pill, Pgymy Chimps, and Degas' Horse. New York: Basic Books.
35. Egarter, C., M. Putz, H. Strohmer, P. Speiser, R. Wenzl, and J. Huber. 1995. "Ovarian function during low-dose oral contraceptive use." Contraception 51(6): 329-333.
36. Egarter, C., M.A. Topcuoglu, M. Imhof, and J. Huber. 1999. "Low-dose oral contraceptives and quality of life." Contraception 59(5): 287-291.
37. Ellison, Peter T. 1988. "Human salivary steroids: Methodological considerations and applications in physical anthropology." Yearbook of Physical Anthropology 31: 115-142.
38. Ellison, Peter T. 1990. "Human ovarian function and reproductive ecology: New hypotheses." American Anthropologist 92: 933-952.
39. Ellison, Peter T., Nadine R. Peacock, and C. Lager. 1989. "Ecology and ovarian function among Lese females of the Ituri Forest, Zaire." American Journal of Physical Anthropology 78(4): 519-526.
40. Elstein, Max. 1994. "Consensus paper. Low-dose contraceptive formulations: Is further reduction in steroid dosage justified?" Advances in Contraception 10(1): 1-4.
41. Elstein, Max and H. Furniss. 1996. "The fiction of an ideal hormonal contraceptive." Advances in Contraception 12(2): 129-138.
42. Endrikat, J., M.-A. Jacques, M. Mayerhofer, C. Pelissier, U. Müller, and B. Düsterberg. 1995. "A 12-month comparative clinical investigation of two low-dose oral contraceptives containing 20 mcg ethinylestradiol/75 mcg gestodene and 20 mcg ethinylestradiol/150 mcg desogestrel, with respect to efficacy, cycle control and tolerance." Contraception 52(4): 229-235.
43. Endrikat, J., U. Müller, and B. Düsterberg. 1997. "A 12-month comparative clinical investigation of two low-dose oral contraceptives containing 20 mcg ethinylestradiol/75 mcg gestodene and 30 mcg ethinylestradiol/75 mcg gestodene with respect to efficacy, cycle control, and tolerance." Contraception 55(3): 131-137.
44. Endrikat, J., M. Cronin, C. Gerlinger, A. Ruebig, and W. Schmidt. 2001a. "Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus 21-day low-dose oral contraceptive regimen containing 20 mcg ethinyl estradiol and 75 mcg gestodene." Contraception 64(2): 99-105.
45. Endrikat, J., M. Cronin, C. Gerlinger, A. Ruebig, W. Schmidt, and B. Düsterberg. 2001b. "Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 mcg ethinyl estradiol and 75 mcg gestodene and a 21-day regimen with 20 mcg ethinyl estradiol and 150 mcg desogestrel." Contraception 64(3): 201-207.
46. Ernst, U., L. Baumgartner, U. Bauer, and G. Janssen. 2002. "Improvement of quality of life in women using a low-dose desogestrel-containing contraceptive: Results of an observational clinical evaluation." European Journal of Contraception and Reproductive Health Care 7(4): 238-243.
47. ESHRE Capri Workshop Group. 2000. "Continuation rates for oral contraceptives and hormone replacment therapy." Human Reproduction 15(8): 1,865-1,871.
48. European Journal of Contraception and Reproductive Health Care (EJCRHC). 1999. "Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 mcg/ethinylestradiol 15 mcg and a 21-day regimen of desogestrel 150 mcg/ethinylestrdiol 20 mcg." European Journal of Contraception and Reproductive Health Care 4 (Supplement 2): 17-25.
49. Family Planning Digest. 1973. "FDA approves pill with least estrogen." Family Planning Digest 2(5): 16.
50. Fitzgerald, Cheryl, W. Feichtinger, Jürgen Spona, Max Elstein, Frank Lüdicke, U. Muller, and C. Williams. 1994. "A comparison of the effects of two monophasic low-dose oral contraceptives on the inhibition of ovulation." Advances in Contraception 10(1): 5-18.
51. Fitzgerald, Cheryl, Max Elstein, and Jürgen Spona. 1999. "Effect of age on the response of the hypothalamo-pituitary ovarian axis to a combined oral contraceptive." Fertility and Sterility 71(6): 1,079-1,084.
52. Fotherby, Kenneth. 1983. "Variability of pharmacokinetic parameters for contraceptive steroids." Journal of Steroid Biochemistry 19(1): 817-820.
53. Fotherby, Kenneth and A.D. Caldwell. 1994. "New progestogens in oral contraception." Contraception 49(1): 1-32.
54. Fotherby, Kenneth, K. Shrimanker et al. 1979. "Rate of metabolism of norethisterone in women from different populations." Contraception 19(1): 39-45.
55. Fotherby, Kenneth, S. Koetsawang, and M. Mathrubutham. 1980. "Pharmacokinetic study of different doses of Depo Provera." Contraception 22(5): 527-538.
56. Fotherby, Kenneth, J. Akpoviroro et al. 1981. "Pharmacokinetics of ethynyloestradiol in women from different populations." Contraception 23(5): 487-497.
57. Fruzzetti, Franca, Andrea R. Genazzani, Cabirla Ricci, Ferdinando de Negri, Chiara Bersi, and Franco Carmassi. 2001. "A 12-month clinical investigation with a 24-day regimen containing 15 mcg ethinyl estradiol plus 60 mcg gestodene with respect to hemostasis and cycle control." Contraception 63(6): 303-307.
58. Garza-Flores, J., V. Valles de Bourges, M. Martinez, L. Vazquez-Estrada, S. Bassol, R. Recio, and G. Perez-Palacios. 1994. "Safety and efficacy of a combined oral contraceptive: Gestodene 75 mcg plus ethinyl estradiol 30 mcg in Mexican women." Advances in Contraception 10(1): 19-26.
59. Gerstman, B. Burt, Thomas P. Gross, Dianne L. Kennedy, Ridgely C. Bennett, Dianne R. Tomita, and Bruce V. Stadel. 1991. "Trends in the content and use of oral contraceptives in the U.S., 1964-1988." American Journal of Public Health 81(1): 90-98.
60. Goldzieher, Joseph W. 1989. "Pharmacology of contraceptive steroids: A brief review." American Journal of Obstetrics and Gynecology 160(5, part 2): 1,260-1,264.
61. Goldzieher, Joseph W. and Steven A. Brody. 1990. "Pharmacokinetics of ethinyl estradiol and mestranol." American Journal of Obstetrics and Gynecology 163(6, part 2): 2,114-2,119.
62. Goldzieher, Joseph W. and N.M. Zamah. 1995. "Oral contraceptive side effects: Where's the beef?" Contraception 52(6): 327-335.
63. Goldzieher, Joseph W., Tazewell S. Dozier, and Armando de la Pena. 1980a. "Plasma levels and pharmacokinetics of ethynyl estrogens in various populations, I. Ethynylestradiol." Contraception 21(1): 1-16.
64. Goldzieher, Joseph W., Tazewell D. Dozier, and Armando de la Pena. 1980b. "Plasma levels and pharmacokinetics of ethynyl estrogens in various populations, II. Mestranol." Contraception 21(1): 17-27.
65. Graham, C.A., R. Ramos, J. Bancroft, C. Maglaya, and T.M.M. Farley. 1995. "The effects of steroidal contraceptives on the well-being and sexuality of women: A double-blind, placebo-controlled, two-centre study of combined and progestogen-only methods." Contraception 52(6): 363-369.
66. Grimes, David A., A.J. Godwin, A. Rubin, J.A. Smith, and M. Lacarra. 1994. "Ovulation and follicular development associated with three low-dose oral contraceptives: A randomized controlled study." Obstetrics and Gynecology 83(1): 29-34.
67. Guitera, V., P. Munoz, J. Castillo, and J. Pascual. 2002. "Quality of life in chronic daily headache: A study in a general population." Neurology 58(7): 1,062-1,065.
68. Hardon, Anita P. 1992. "The needs of women versus the interests of family planning personnel, policy-makers and researchers: Conflicting views on the safety and acceptability of contraceptives." Social Science & Medicine: 35(6): 753-766.
69. Hardon, Anita P. 1994. "The development of contraceptive technologies: A feminist critique." Focus on Gender 2: 40-44.
70. Hardon, Anita P. 1997. "Women's views and experiences of hormonal contraceptives: What we know and what we need to find out." In Beyond Acceptability. Eds. T.K. Sundari Ravidrun, M. Berer, and J. Cottingham. London: Reproductive Health Matters for the World Health Organization. Pp. 68-77.
71. Hatcher, Robert A., James Trussell, Felicia Stewart, Willard Cates Jr., Gary K. Stewart, Felicia Guest, and Deborah Kowal. 1998. Contraceptive Technology, 17th revised edition. New York: Ardent Media.
72. Henry, R. 2001. Contraceptive Practice in Quirino Province, Philippines: Experiences of Side Effects. Calverton, MD: Macro International.
73. Hirvonen, E., H. Allonene, M. Antitila, T. Kulmala, T. Ranta, H. Rautiainen, P. Sipila, and P. Ylostalo. 1995. "Oral contraceptives containing natural estrogen for premenopausal women." Maturitas 1(1): 27-32.
74. Holroyd, Kenneth A., Peter Malinowski, M. Katherine Davis, and Gay L. Lipchik. 1999. "The three dimensions of headache impact: Pain, disability and affective distress." Pain 83(3): 571-578.
75. Holt, Victoria L., Delia Scholes, Kristine G. Wicklund, Kara L. Cushing-Haugen, and Janet R. Daling. 2005. "Body mass index, weight, and oral contraceptive failure risk." Obstetrics & Gynecology 105(1): 46-52.
76. Huezo, C.M. 1998. "Current reversible contraceptive methods: A global perspective." International Journal of Gynecology and Obstetrics 62 (Supplement 1): S3-S15.
77. Hull, Terence H. 1998. "The challenge of contraceptive implant removals in East Nusa Tenggara, Indonesia." International Family Planning Perspectives 24(4): 176-179.
78. Ismail, M.T. 1994. "A prospective study of a monophasic oral contraceptive containing 30 mcg ethinyl oestradiol and 150 mcg desogestrel (Marvelon)." Malaysian Journal of Reproductive Health 12(1): 43-48.
79. Jain, Anrudh K. 1989. "Fertility reduction and the quality of family planning services." Studies in Family Planning 20(1): 1-16.
80. Jaisamrarn, U., D. Reinprayoon, and P. Virutamasen. 2001. "Clinical study of a monophasic pill containing 20 mcg ethinylestradiol and 150 mcg desogestrel in Thai women." Journal of the Medical Association of Thailand 84 (Supplement 1): S377-S383.
81. Janowitz, B., T.T. Kane, J.M. Arruda, D.L. Covington, and L. Morris. 1986. "Side effects and discontinuation of oral contraceptive use in southern Brazil." Journal of Biosocial Science 18(3): 261-271.
82. Jasienska, G. and P.T. Ellison. 1993. "Heavy workload impairs ovarian function in Polish peasant women." American Journal of Physical Anthropology Supplement 16: 117-118.
83. Kaunitz, Andrew M. 2004. "Enhancing oral contraceptive success: The potential of new formulations." American Journal of Obstetrics and Gynecology 190(Supplement): S23-S29.
84. Kaunitz, Andrew M. and H. Ory. 1997. "Estrogen component of OCs." Dialogues in Contraception 5(4, Supplement): 1-6.
85. Kendler, K.S., N.G. Martin, A.C. Health, D. Handelsman, and L.U. Eaves. 1988. "A twin study of the psychiatric side effects of oral contraceptives." Journal of Nervous and Mental Disorders 176(3): 153-160.
86. Kernick, D.P. and D. Reinhold. 2002. "The prevalence and treatment of headache sufficient to impact on the quality of life of undergraduate students entering university." Current Medical Research and Opinion 18(8): 462-464.
87. Khan, M. Asaduzzaman. 2001. "Side effects and oral contraceptive discontinuation in rural Bangladesh." Contraception 64(3): 161-167.
88. Koenig, Michael A., Mian Bazle Hossain, and Maxine Wittaker. 1997. "The influence of quality of care upon contraceptive use in rural Bangladesh." Studies in Family Planning 28(4): 278-289.
89. Koetsawang, Suporn. 1984. "Side effects and oral contraceptives in Oriental women, Singapore." Journal of Obstetrics and Gynaecology 15 (Supplement 1): 44-51.
90. Koetsawang, Suporn, Chalermporn Charoenvisal, Laddawan Banharnsupawat, Suwat Singhakovin, Ouyporn Kaewsuk, and Sermsak Punnahitanont. 1995. "Multicenter trial of two monophasic oral contraceptives containing 30 mcg ethinyl estradiol and either desogestrel or gestodene in Thai women." Contraception 51(4): 225-229.
91. LaGuardia, Katherine D., Gary Shangold, Alan Fisher, Andrew Friedman, Michael Kafrissen, and the Norgestimate Study Group. 2003. "Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradiol." Contraception 67(6): 431-437.
92. Lammers, P. and M. op ten Berg. 1991. "Phase III clinical trial with a new oral contraceptive containing 150 mcg desogestrel and 20 mcg ethinylestradiol." Acta Obstetica et Gynecologica Scandinavica 70(6): 497-500.
93. Lawrence, H. 1997. "How early-cycle side effects discourage pill use." Contemporary OB/GYN 42: 45-70.
94. Lei, Z.-W., S.C. Wu, R.J. Garceau, S. Jiang, Q.-Z. Yang, W.-L. Wang, and T.C. Vander Meulen. 1996. "Effect of pre-treatment counseling on discontinuation rates in Chinese women given depot-medroxyprogesterone acetate for contraception." Contraception 53(6): 357-361.
95. Lidegaard, Øjvind and Svend Kreiner. 2002. "Contraceptives and cerebral thrombosis: A five-year national case-control study." Contraception 65(3): 197-205.
96. Lidegaard, Øjvind, Birgette Edström, and Svend Kreiner. 2002. "Oral contraceptives and venous thromboembolism: A five-year national case-control study." Contraception 65(3): 187-196.
97. Lipson, Susan F. and Peter T. Ellison. 1989. "Development of protocols for the application of salivary steriods to field conditions." American Journal of Human Biology 1: 249-255.
98. Lipson, Susan F. and Peter T. Ellison. 1992. "Normative study of age variation in salivary progesterone profiles." Journal of Biosocial Science 24(2): 233-244.
99. Lu, Y.-C., G.R Bentley, P.H.Gann, K.R. Hodges, and R.T. Chatterton. 1999. "Salivary estradiol and progesterone levels in conception and non-conception cycles in women. Evaluation of a new assay for salivary estradiol." Fertility and Sterility 71(5): 863-868.
100. Lüdicke, Frank, Helen Sullivan, Jürgen Spona, and Max Elstein. 2001. "Dose finding in a low-dose 21-day combined oral contraceptive containing gestodene." Contraception 64: 243-248.
101. Majumdar, Sumit R. et al. 2003. "Chronic acid-related disorders are common and underinvestigated." American Journal of Gastroenterology 98(11): 2,409-2,414.
102. Malamud, D. and L. Tabak (eds.). 1993. "Saliva as a diagnostic fluid." Annals of the New York Academy of Sciences 694: 342.
103. McLaurin, Vivian L. and Thomas R. Dunson. 1991. "A comparative study of 35 mcg and 50 mcg combined oral contraceptives: Results from a multicentre clinical trial." Contraception 44(5): 489-503.
104. Mishell, D.R. 1993. "Noncontraceptive benefits of oral contraceptives." Journal of Reproductive Medicine 38 (12, Supplement): 1,021-1,029.
105. O'Brien, B. and S. Naber. 1992. "Nausea and vomiting during pregnancy: Effects on the quality of women's lives." Birth 19(3): 138-143.
106. Oddens, Bjorn J. 1999. "Women's satisfaction with birth control: A population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural family planning, and sterilization among 1,466 women." Contraception 59(5): 277-286.
107. Panter-Brick, C., D.S. Lotstein, and P.T. Ellison. 1993. "Seasonality of reproductive function and weight loss in rural Nepali women." Human Reproduction 8(5): 684-690.
108. Perone, N. 1994. "The progestins." In Pharmacology of the Contraceptive Steroids. Eds. J.W. Goldzieher and K. Fotherby. New York: Raven Press. Pp. 5-25.
109. Phillips, James F., Axel Mundigo, and Aphichat Chamratrithirong. 1990. "Correlates of contraceptive use continuity." Journal of Family Welfare 36(3): 3-17.
110. Poindexter, A.N., R. Burkman, A.C. Fisher, and K.D. LaGuardia. 2003. "Cycle control, tolerability, and satisfaction among women switching from 30-35 mcg ethinyl estradiol containing oral contraceptives to the triphasic norgestimate/25 mcg ethinyl estradiol containing oral contraceptive Ortho tri-cyclen LO." International Journal of Fertility and Women's Medicine 48(4): 163-172.
111. RamaRao, Saumya and Raji Mohanam. 2003. "The quality of family planning programs: Concepts, measurements, interventions and effects." Studies in Family Planning 34(4): 227-248.
112. RamaRao, Saumya, Marlina Lacuesta, Marilou Costello, Blesilda Pangolibay, and Heidi Jones. 2003. "The link between quality of care and contraceptive use." International Family Planning Perspectives 29(2): 76-83.
113. Reisman, H., D. Martin, and M.J. Gast. 1999. "A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100 mcg levonorgestrel with 20 mcg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol." American Journal of Obstetrics and Gynecology 181(5, part 2): S45-S52.
114. Ringheim, Karin. 1996. "Precursors of induced abortion: The role of experienced and perceived contraceptive side effects." Poster session, Annual Meetings of the Population Association of America, New Orleans, 9-11 May.
115. Rivera, Roberto, Irene Yacobson, and David Grimes. 1999. "The mechanism of action of hormonal contraceptives and intrauterine devices." American Journal of Obstetrics and Gynecology 181(5, part 1): 1,263-1,269.
116. Rosenberg, Michael J. and S.C. Long. 1992. "Oral contraceptives and cycle control: A critical review of the literature." Advances in Contraception 8(Supplement 1): 35-45.
117. Rosenberg, Michael J., M.S. Waugh, and T.E. Meehan. 1995a. "Use and misuse of oral contraceptives: Risk indicators for poor pill taking and discontinuation." Contraception 51(5): 283-288.
118. Rosenberg, Michael, M. Burnhill, M. Waugh, and David A. Grimes. 1995b. "Compliance and oral contraceptives: A review." Contraception 52(3): 137-141.
119. Rosenberg, Michael, M.S. Waugh, and J.E. Higgens. 1996. "The effect of desogestrel, gestodene, and other factors on spotting and bleeding." Contraception 53(2): 85-90.
120. Rosenberg, Michael, M. Waugh, and M. Burnhill. 1998. "Compliance, counseling and satisfaction with oral contraceptives: A prospective evaluation." Family Planning Perspectives 30(2): 89-92.
121. Rosenberg, Michael J., Andrea Meyers, and Vikki Roy. 2000. "Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: A randomized trial of 20 mcg and 35 mcg estrogen preparations." Contraception 60(6): 321-329.
122. Roumen, F.J.M.E., D. Apter, T.M.T. Mulders, and T.O.M. Dieben. 2001. "Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol." Human Reproduction 16(3): 469-475.
123. Salway, Sarah, Vincent Fauveau and J. Chakrabarty. 1994. "Introducing the low-dose pill to Bangladesh: Issues of continuation and failure." Contraception 49(2): 171-183.
124. Sanogo, Diouratié, Saumya RamaRao, Heidi Jones, Penda N'diaye, Bineta M'bow, and Cheikh Bamba Diop. 2003. "Improving quality and contraceptive use in Senegal." African Journal of Reproductive Health 7(2): 57-73.
125. Sartoretto, J.N. and J.C. Ortega-Recio. 1974. "Clinical evaluation of a low dosage estrogen-progesterone association (100 mcg of dnorgestrel and 20 mcg of ethinyl estradiol). Revista Brasileira de Clínica e Terapêutica 3: 399-404.
126. Schwartz, B.S., W.F. Stewart, and R.B. Lipton. 1997. "Lost workdays and decreased work effectiveness associated with headache in the workplace." Journal of Occupational and Environmental Medicine 39(4): 320-327.
127. Seaton, B. and D. Riad-Fahmy. 1980. "Use of salivary progesterone to monitor menstrual cycles in Bangladeshi women." Journal of Endocrinology 87: 21P
128. Serfaty, D. and M.L. Vree. 1998. "A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 mcg ethinylestradiol and either 150 mcg desogestrel or 75 mcg gestodene." European Journal of Contraception and Reproductive Health Care 3(4): 179-189.
129. Sherif, Katherine. 1999. "Benefits and risks of oral contraceptives." American Journal of Obstetrics and Gynecology 180(6, part 2): S323-S328.
130. Singh, Susheela and Dierdre Wulf. 1994. "Estimated levels of induced abortion in six Latin American countries." International Family Planning Perspectives 20(1): 4-11.
131. Sitruk-Ware, Régine, Margaret Small, Narender Kumar, Yun-Yen Tsong, Kalyan Sundaram, and Theodore M. Jackanicz. 2003. "Nestorone: Clinical applications for contraception and HRT." Steroids 68(10-13): 907-913.
132. Smith, C., C. Crowther, J. Beilby, and J. Dandeaux. 2000. "The impact of nausea and vomiting on women: A burden of early pregnancy." Australian and New Zealand Journal of Obstetrics and Gynaecology 40(4): 397-401.
133. Spieler, J. 2004. Biologist, USAID. Personal communication.
134. Stadel, Bruce V., Phyllis M. Sternthal, James J. Schlesselman, Margaret B. Douglas, W. Dallas Hall, Lalita Kaul, and Balwant Ahluwalia. 1980. "Variation of ethinylestradiol blood levels among healthy women using oral contraceptives." Fertility and Sterility 33(3): 257-260.
135. Steele, Fiona and Siân Curtis. 2003. "Appropriate methods for analyzing the effect of method choice on contraceptive discontinuation." Demography 40(1): 1-22.
136. Stewart, W.F., J.A. Ricci,, E. Chee, D. Morganstein, and R. Lipton. 2003. " Lost productive time and cost due to common pain conditions in the U.S. workforce." Journal of the American Medical Association 290(18): 2,443-2,454.
137. Strickler, Jennifer A., Robert J. Magnani, H. Gilman McCann, Lisanne F. Brown, and Janet C. Rice. 1997. "The reliability of reporting of contraceptive behavior in DHS calendar data: Evidence from Morocco." Studies in Family Planning 28(1): 44-53.
138. Sulak, Patricia, Joel Lippman, Cynthia Siu, Joseph Massaro, and Amy Godwin. 1999. "Clinical comparison of triphasic norgestimate/35 mcg ethinyl estradiol and monophasic norethindrone acetate/20 mcg ethinyl estradiol: Cycle control, lipid effects, and user satisfaction." Contraception 59(3): 161-166.
139. Sullivan, Helen, Hilary Furniss, Jürgen Spona, and Max Elstein. 1999. "Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 mcg) and ethinyl estradiol (15 mcg) on ovarian activity." Fertility and Sterility 72(1): 115-120.
140. Sunyavivat, S., T. Chumnijarakij, Y. Onthuam, A.H. Mehyar, B. Busca, and B. Christian. 1983. "Reasons for discontinuing contraception among women in Bangkok." Bulletin of the World Health Organization 61(5):861-865.
141. Swallow, B., S. Lindow, E. Masson, and D. Hay. 2004. "Psychological health in early pregnancy: Relationship with nausea and vomiting." Journal of Obstetrics and Gynaecology 24(1): 28-32.
142. Talwar, P.P. and G.S. Berger. 1977. "The relation of body weight to side effects associated with oral contraceptives." British Medical Journal 25 June 1(6,007): 1,637-1,638.
143. Tanis, B.C. et al. 2001. "Oral contraceptives and the risk of myocardial infarction." New England Journal of Medicine 345(25): 1,787-1,793.
144. Trlin, A.D. and P.E. Perry. 1982. "The oral contraceptive pill: Use, user satisfaction, side effects and fears among Manawatu." New Zealand Medical Journal 95(717): 700-703.
145. Trottier, Dorace A., Linda S. Potter, Barbara A. Taylor, and Lucinda H. Glover. 1994. "User characteristics and oral contraceptive compliance in Egypt." Studies in Family Planning 25(5): 284-292.
146. Tyrer, L. 1999. "Introduction of the pill and its impact." Contraception 59(Supplement 1): 11S-16S.
147. Van der Mooren, M.J., C. Klipping, B. van Aken, E. Helmerhorst, D. Spielmann, and C. Kluft. 1999. "A comparative study of the effects of gestodene 60 mcg/ethinylestradiol 15 mcg and desogestrel 150 mcg/ ethinylestrdiol 20 mcg on hemostatic balance, blood lipid levels and carbohydrate metabolism." European Journal of Contraception and Reproductive Health Care 4(Supplement 2): 27-35.
148. van der Walt, L.A., E.N. Wilmsen, J. Levin, and T. Jenkins. 1977. "Endocrine studies on the San ('Bushmen') of Botswana." South African Medical Journal 52: 230-232.
149. Vitzthum, Virginia J. 1990. An Adaptational Model of Ovarian Function Research Report No. 90-200. Ann Arbor, MI: Population Studies Center, University of Michigan.
150. Vitzthum, Virginia J. 1997. "Flexibility and paradox: The nature of adaptation in human reproduction." In The Evolving Female: A Life History Perspective. Eds. A. Zihlman, A. Galloway, and M.E. Morbeck. Princeton, NJ: Princeton University Press. Pp. 242-258.
151. Vitzthum, Virginia J. 2001. "Why not so great is still good enough: Flexible responsiveness in human reproductive functioning." In Reproductive Ecology and Human Evolution. Ed. P.T. Ellison. New York: Aldine de Gruyter. Pp. 179-202.
152. Vitzthum, Virginia J., Peter T. Ellison, and Sarah Sukalich. 1994. "Salivary progesterone profiles of indigenous Andean women." American Journal of Physical Anthropology (Supplement 18): 201-202.
153. Vitzthum, Virginia J., Gillian R. Bentley, Esperanza Caceres, Hilde Spielvogel, K. Crone, L. May, and R.T. Chatterton. 1998. "Correlates of conception in high altitude Aymara women." The FASEB Journal 12: A726.
154. Vitzthum, Virginia J., Peter T. Ellison, Sarah Sukalich, Esperanza Caceres, and Hilde Spielvogel. 2000. "Does hypoxia impair ovarian function in Bolivian women indigenous to high altitude?" High Altitude Medicine and Biology 1(1): 39-49.
155. Vitzthum, Virginia J., Gillian R. Bentley, Hilde Spielvogel, Esperanza Caceres, Jonathan Thornburg, Lary Jones, Sarah Shore, K.R. Hodges, and R.T. Chatterton. 2002. "Salivary progesterone levels and rate of ovulation are significantly lower in poorer than in better-off urban-dwelling Bolivian women." Human Reproduction 17(7): 1,906-1,913.
156. Vitzthum, Virginia J., Hilde Spielvogel, and Jonathan Thornburg. 2004. "Interpopulational differences in progesterone levels during conception and implantation in humans." Proceedings of the National Academy of Sciences (United States) 101: 1,443-1,448.
157. Watkins, Elizabeth Siegel. 1998. On the Pill: A Social History of
158. Widyantoro, Ninuk. 1994. "The story of Norplant implants in Indonesia." Reproductive Health Matters 2(3): 20-30.
159. World Health Organization (WHO). 1978. "Multinational comparative clinical evaluation of two long-acting injectable contaceptive steroids: Norethisterone oenanthate and medroxyprogesterone acetate, 2. Bleeding patterns and side effects." Contraception 17(6): 395-406.
160. World Health Organization Task Force on Psychosocial Research in Family Planning and Task Force on Service Research in Family Planning. 1980. "User preferences for contraceptive methods in India, Korea, the Philippines, and Turkey." Studies in Family Planning 11(9/ 10): 267-273.
161. World Health Organization Task Force on Psychosocial Research in Family Planning and Task Force on Service Research in Family 1982. "A randomized, double-blind study of six combined oral contraceptives." Contraception 25(3): 231-241.
162. Yen, S.C., R.B. Jaffe, and R.L. Barbieri. 1999. Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management. Philadelphia: W.B. Saunders.
163. Yuzpe, A.A. 2002. "Oral contraception: Trends over time." Journal of Reproductive Medicine 47(11, Supplement): 967-973.
164. Ziaei, S., L. Rajaei, S. Faghihzadeh, and M. Lamyian. 2002. "Comparative study and evaluation of side effects of low-dose contraceptive pills administered by the oral and vaginal route." Contraception 65(5): 329-331.
165. Zimmerman, Margot, Joan Haffey, Elizabeth Crane, Danusia Szumowski, Frank Alvarez, Patama Bhiromrut, Vivian Brache, Firman Lubis, Maher Salah, Mamdouh Shaaban et al. 1990. "Assessing the acceptability of Norplant® implants in four countries: Findings from focus group research." Studies in Family Planning 21(2): 92-103.